{"nctId":"NCT01712438","briefTitle":"Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients","startDateStruct":{"date":"2013-02"},"conditions":["Severe Hemophilia A"],"count":110,"armGroups":[{"label":"Human cl rhFVIII","type":"EXPERIMENTAL","interventionNames":["Biological: Human cl rhFVIII"]}],"interventions":[{"name":"Human cl rhFVIII","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male patients\n* Severe Hemophilia A (FVIII:C \\<1%)\n* No previous treatment with FVIII concentrates or other blood products containing FVIII\n\nExclusion Criteria:\n\n* Diagnosis with a coagulation disorder other than Hemophilia A\n* Severe liver or kidney disease\n* Concomitant treatment with any systemic immunosuppressive drug","healthyVolunteers":false,"sex":"MALE","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Immunogenicity of Human-cl rhFVIII: Incidence of Inhibitors","description":"The number of patients developing FVIII inhibitors was observed during the observation period by assessing inhibitor development using the modified Bethesda assay (Nijmegen modification). The definitions for thresholds were ≥0.6 to \\<5 BU/mL for a \"low titre\" inhibitor and ≥5 BU/mL for a \"high-titre\" inhibitor.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null}]}]}]},{"type":"SECONDARY","title":"Frequency of Spontaneous Break-through Bleeds","description":"The annualized bleeding rate (ABR) was calculated during inhibitor-free periods for spontaneous bleeding events (BEs) during prophylactic treatment with Human cl rhFVIII","paramType":"MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.976","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy of Human-cl rhFVIII for the Treatment of Bleeds","description":"A personal efficacy assessment to assess the efficacy of Human-cl rhFVIII for the on-demand treatment of bleeding episodes. Efficacy was assessed using a four-point scale (excellent, good, moderate, none).","paramType":"COUNT_OF_UNITS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"510","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"237","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"51","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null}]}]}]},{"type":"SECONDARY","title":"Efficacy of Human-cl rhFVIII for Surgical Prophylaxis","description":"An overall efficacy assessment to assess the efficacy of human-cl rhFVIII in surgical prophylaxis of minor and major surgeries. The efficacy assessment was analyzed using a four-point scale (excellent, good, moderate, none).","paramType":"COUNT_OF_UNITS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"8","spread":null},{"groupId":"OG002","value":"15","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null},{"groupId":"OG002","value":"3","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]},{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"The Occurrence of Any Adverse Event (AE)","description":"The frequency of AEs, as monitored throughout the whole study by the number of patients with at least one adverse event occurrence.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"101","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"78","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":48,"n":108},"commonTop":["Pyrexia","Nasopharyngitis","Factor VIII inhibition","Anaemia","Rhinitis"]}}}